Spectrum reports Q1 EPS (5c), consensus (16c) Reports Q1 revenue $38.7M, consensus $36.42M. Says pivotal data in relapsed/refractory peripheral T-cell lymphoma from late-stage drug Belinostat to be presented as an oral presentation at ASCO 2013; the company expects to submit an NDA this summer. Company expects enrollment in the Captisol-enabled melphalan study in multiple myeloma to be completed in 2013, with NDA submission in 2014.
Subscribe for More Information
